Literature DB >> 2859845

Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique.

A Takenaka, C J Gibbs, D C Gajdusek.   

Abstract

The 76--118 strain of Hantaan virus was titrated in E6 (Vero) cells by the plaque method using agarose overlay medium. Visible plaques, formed 10 days post-infection, were uniformly 2--3 mm in diameter. Dose-response experiments showed that a single infectious particle initiated the formation of a plaque. Infectivity titers by the plaque method were equivalent to those obtained by the endpoint method (TCID50) using the immunofluorescence antibody technique (IFA) for antigen detection. The single-cycle growth pattern of the virus showed an eclipse phase of 7 to 9 hours, with production of cell-free infectious virus 18 hours post-infection. Plaque reduction neutralization tests suggested that complement enhanced the neutralizing activity of sera; rat sera were particularly complement-dependent. The plaque reduction neutralization test was about 10 times more sensitive than the TCID50 neutralization test. Convalescent phase sera from patients with hemorrhagic fever with renal syndrome (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing Hantaan virus, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859845     DOI: 10.1007/bf01378972

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  14 in total

1.  Isolation of virus causing hemorrhagic fever with renal syndrome (HFRS) through a cell culture system.

Authors:  T Kitamura; C Morita; T Komatsu; K Sugiyama; J Arikawa; S Shiga; H Takeda; Y Akao; K Imaizumi; A Oya; N Hashimoto; S Urasawa
Journal:  Jpn J Med Sci Biol       Date:  1983-02

Review 2.  Korean hemorrhagic fever.

Authors:  H W Lee
Journal:  Prog Med Virol       Date:  1982

3.  Seroepidemiology of Hantaan virus.

Authors:  C J Gibbs; A Takenaka; M Franko; D C Gajdusek; M D Griffin; J Chields; G W Korch; D Wartzok
Journal:  Lancet       Date:  1982-12-18       Impact factor: 79.321

4.  Hantaan virus, aetiological agent of Korean haemorrhagic fever, has Bunyaviridae-like morphology.

Authors:  J D White; F G Shirey; G R French; J W Huggins; O M Brand; H W Lee
Journal:  Lancet       Date:  1982-04-03       Impact factor: 79.321

5.  Intracerebral inoculation of suckling mice with Hantaan virus.

Authors:  T F Tsai; S Bauer; J B McCormick; T Kurata
Journal:  Lancet       Date:  1982-08-28       Impact factor: 79.321

6.  Korean hemorrhagic fever: propagation of the etiologic agent in a cell line of human origin.

Authors:  G R French; R S Foulke; O A Brand; G A Eddy; H W Lee; P W Lee
Journal:  Science       Date:  1981-03-06       Impact factor: 47.728

7.  Morphological identification of the agent of Korean haemorrhagic fever (Hantaan virus)as a member of the Bunyaviridae.

Authors:  J B McCormick; D R Sasso; E L Palmer; M P Kiley
Journal:  Lancet       Date:  1982-04-03       Impact factor: 79.321

8.  Propagation of Korean hemorrhagic fever virus in laboratory rats.

Authors:  P W Lee; H L Amyx; C J Gibbs; D C Gajdusek; H W Lee
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

9.  Analysis of Hantaan virus RNA: evidence for a new genus of bunyaviridae.

Authors:  C S Schmaljohn; J M Dalrymple
Journal:  Virology       Date:  1983-12       Impact factor: 3.616

10.  Etiologic studies of epidemic hemorrhagic fever (hemorrhagic fever with renal syndrome).

Authors:  G Song; C S Hang; X Z Qui; D S Ni; H X Liao; G Z Gao; Y L Du; J K Xu; Y S Wu; J N Zhao; B X Kong; Z S Wang; Z Q Zhang; H K Shen; N Zhou
Journal:  J Infect Dis       Date:  1983-04       Impact factor: 5.226

View more
  7 in total

1.  Differential susceptibility and resistance of immunocompetent and immunodeficient mice to fatal Hantaan virus infection.

Authors:  T Nakamura; R Yanagihara; C J Gibbs; H L Amyx; D C Gajdusek
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

2.  The murine model for Hantaan virus-induced lethal disease shows two distinct paths in viral evolutionary trajectory with and without ribavirin treatment.

Authors:  Dong-Hoon Chung; Åke Västermark; Jeremy V Camp; Ryan McAllister; Susanna K Remold; Yong-Kyu Chu; Carl Bruder; Colleen B Jonsson
Journal:  J Virol       Date:  2013-07-31       Impact factor: 5.103

3.  Ribavirin reveals a lethal threshold of allowable mutation frequency for Hantaan virus.

Authors:  Dong-Hoon Chung; Yanjie Sun; William B Parker; Jeffrey B Arterburn; Al Bartolucci; Colleen B Jonsson
Journal:  J Virol       Date:  2007-08-15       Impact factor: 5.103

4.  Neutralizing Antibodies to Severe Fever with Thrombocytopenia Syndrome Virus 4 Years after Hospitalization, China.

Authors:  Yu-Ting Huang; Li Zhao; Hong-Ling Wen; Yi Yang; Hao Yu; Xue-Jie Yu
Journal:  Emerg Infect Dis       Date:  2016-11       Impact factor: 6.883

5.  An Improved Enzyme-Linked Focus Formation Assay Revealed Baloxavir Acid as a Potential Antiviral Therapeutic Against Hantavirus Infection.

Authors:  Chuantao Ye; Dan Wang; He Liu; Hongwei Ma; Yangchao Dong; Min Yao; Yuan Wang; Hui Zhang; Liang Zhang; Linfeng Cheng; Zhikai Xu; Yingfeng Lei; Fanglin Zhang; Wei Ye
Journal:  Front Pharmacol       Date:  2019-10-16       Impact factor: 5.810

6.  Development of a Comparative European Orthohantavirus Microneutralization Assay With Multi- Species Validation and Evaluation in a Human Diagnostic Cohort.

Authors:  Tabitha E Hoornweg; Ilse Zutt; Ankje de Vries; Miriam Maas; Marieke N Hoogerwerf; Tatjana Avšič-Županc; Miša Korva; Johan H J Reimerink; Chantal B E M Reusken
Journal:  Front Cell Infect Microbiol       Date:  2020-12-22       Impact factor: 5.293

7.  Multiplex PCR-based titration (MPBT) assay for determination of infectious titers of the three Sabin strains of live poliovirus vaccine.

Authors:  Hasmik Manukyan; Elvira Rodionova; Tatiana Zagorodnyaya; Tsai-Lien Lin; Konstantin Chumakov; Majid Laassri
Journal:  Virol J       Date:  2019-10-28       Impact factor: 4.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.